TRAIN · Tumor Regulation Assisted by Immunity and Nanotechnology

Tumor Regulation Assisted by Immunity and Nanotechnology

Cancer is the leading cause of death among Europeans under the age of 65, with one in two people expected to face a cancer diagnosis during their lifetime. Despite important advances in prevention, diagnosis, and treatment, cancer continues to claim millions of lives, place heavy burdens on families, and generate significant pressure on healthcare systems and national economies. These realities highlight an urgent need for new therapeutic approaches, particularly for aggressive cancers such as pancreatic ductal adenocarcinoma (PAAD), which has a dismal prognosis and remains one of the most lethal malignancies in Europe. In response to this urgent medical and societal need, the European Union has launched “Europe’s Beating Cancer Plan”, which aims to reduce the burden of cancer by supporting innovative treatments, improving patient outcomes, and addressing inequalities in cancer care. Within this strategic framework, cancer immunotherapy represents one of the most promising advances, offering a durable and personalized treatment option. However, immunomodulation for cancer therapy is still in its infancy, and critical knowledge gaps remain, particularly regarding how tumour metabolism and immune cell activity can be regulated to improve therapeutic efficacy. The TRAIN project was conceived to address this gap by investigating a new class of molecularly engineered peptide nanomaterials capable of modulating amino acid metabolism within the tumour microenvironment (TME). The overarching goal was to create enzyme-responsive nanomaterials that release immunomodulatory amino acids, thereby enhancing the effectiveness of cancer immunotherapies. The TRAIN project provides a clear pathway from fundamental science to translational potential. By demonstrating proof-of-concept for enzyme-responsive peptide nanomaterials, the project contributes to new therapeutic strategies for PAAD, a cancer of high unmet clinical need.

Data: CORDIS, © European Union